United States· US:55513-180_20150720-3435-4d6c-8eb1-55e6bc56cdce
BKEMV
A eculizumab product containing eculizumab, registered in United States by Amgen Inc. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Eculizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AJ01 (eculizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Eculizumab · ATC L04AJ01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ECULIZUMAB
- Manufacturer
- Amgen Inc
- Country
- United States (US)
- ATC code
- L04AJ01
- ATC class
- Eculizumab
- Defined daily dose
- 64 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 5, 2026
Packs & prices · 2
- ndc1155513180011 VIAL in 1 CARTON (55513-180-01) / 30 mL in 1 VIAL
- ndc1155513-180-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for eculizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eculizumab · interactions on record
2 records
Same medicine, other countries
Eculizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenSoliris 10 mg/ml Koncentrat till infusionsvätska, lösningAlexion Europe SAS
- IrelandBEKEMV 300 mg Concentrate for solution for infusionAmgen Technology (Ireland) Unlimited Company
- NorwayBekemvAmgen Technology Ireland
- PolandBekemvAmgen Technology (Ireland) UC
- CzechiaBEKEMVAmgen Europe B.V., Breda
- SpainBEKEMV 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Technology (Ireland) Unlimited Company
- FinlandBEKEMVAmgen Europe B.V.
- FranceBEKEMV 300 mg, solution à diluer pour perfusionAMGEN TECHNOLOGY (IRELAND)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bekemv, Soliris
- Liechtenstein · Soliris
- Norway · Bekemv, Soliris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c07ab99f-4c24-4969-9dec-4a06580454cc GET /v1/drugs/c07ab99f-4c24-4969-9dec-4a06580454cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "300",
"substance": "ECULIZUMAB",
"productndc": "55513-180",
"dosage_form": "INJECTION, SOLUTION, CONCENTRATE",
"dea_schedule": null,
"strength_unit": "mg/30mL",
"application_number": "BLA761333",
"marketing_category": "BLA"
}See everything about eculizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.